Skip to content
HowShorted

Corbus Pharmaceuticals Holdings, Inc. short interest in 2021

In 2021, Corbus Pharmaceuticals Holdings, Inc.'s disclosed short interest ran from 19.33% of shares outstanding on 15 Jan 2021 to 4.57% on 31 Dec 2021, a change of -14.76 percentage points. The year's high was 26.35% on 12 Feb 2021 and its low 4.57% on 31 Dec 2021, averaging 9.36% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.11 days on 15 Sep 2021. Full history: Corbus Pharmaceuticals Holdings, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Corbus Pharmaceuticals Holdings, Inc. in 2021

2021 in figures

Start of year
19.33% (15 Jan 2021)
End of year
4.57% (31 Dec 2021)
Change
-14.76 pp
High
26.35% (12 Feb 2021)
Low
4.57% (31 Dec 2021)
Average
9.36%
Highest days to cover
10.11 (15 Sep 2021)
SEC filings marked
8

Every report in 2021

Corbus Pharmaceuticals Holdings, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202119.33%2.27
29 Jan 202117.48%1.23
12 Feb 202126.35%1.00
26 Feb 202116.15%1.00
15 Mar 20219.32%1.6110-K filed, results (8-K)
31 Mar 20218.68%2.62
15 Apr 202110.75%4.79
30 Apr 202111.00%6.08
14 May 202110.99%6.0510-Q filed, results (8-K)
28 May 202110.25%5.90
15 Jun 202111.58%5.73
30 Jun 20216.69%1.64
15 Jul 20216.21%6.23
30 Jul 20215.66%6.34
13 Aug 20215.75%5.5910-Q filed, results (8-K)
31 Aug 20215.91%8.77
15 Sep 20215.67%10.11
30 Sep 20215.27%5.96
15 Oct 20215.31%8.17
29 Oct 20215.73%7.46
15 Nov 20215.76%4.8910-Q filed, results (8-K)
30 Nov 20215.10%5.96
15 Dec 20215.11%7.50
31 Dec 20214.57%4.01

See also: Corbus Pharmaceuticals Holdings, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.